News

Gritstone bio and the Coalition for Epidemic Preparedness Innovations (CEPI) have signed a funding agreement to advance the development of the former’s second-generation Covid-19 vaccine programme (CORAL) against

Pfizer and its partner BioNTech have submitted the initial data of an early-stage trial to the US Food and Drug Administration (FDA) to support the authorisation of a

Merck, called MSD outside the US and Canada, has initiated a rolling submission to Health Canada for molnupiravir, an investigational oral antiviral therapy for the treatment of Covid-19.

Moderna has announced that in a new study its Covid-19 messenger ribonucleic acid (mRNA) vaccine showed durable efficacy in generating neutralising antibodies against SARS-CoV-2 variants of concern. The

The US Food and Drug Administration (FDA) has authorised additional doses of Pfizer-BioNTech and Moderna Covid-19 vaccines for certain people with compromised immune systems. The regulatory agency has

Biotherapeutics company GentiBio has raised $157m through a Series A funding round, which was led by Matrix Capital Management. The firm plans to use the proceeds from the

The US Food and Drug Administration (FDA) has declined to approve AstraZeneca and FibroGen’s new drug application (NDA) for roxadustat to treat anaemia associated with chronic kidney disease

The US Food and Drug Administration (FDA) has granted priority review for Merck’s supplemental biologics license application (sBLA) for KEYTRUDA (pembrolizumab) as adjuvant therapy for patients with renal

Biotechnology firm Moderna and Canadian government have signed a memorandum of understanding (MoU) to construct a new messenger RNA (mRNA) vaccine manufacturing facility in Canada. The latest deal